Ceccarini, G. http://orcid.org/0000-0003-0701-642X
Pelosini, C.
Paoli, M.
Tyutyusheva, N.
Magno, S.
Gilio, D.
Palladino, L.
Sessa, M. R.
Bertelloni, S.
Santini, F.
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (PRIN 2020NCKXBR)
Article History
Received: 7 December 2023
Accepted: 9 January 2024
First Online: 15 February 2024
Declarations
:
: GC has received fees for consulting and/or received travel funds or participated in studies from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo-Nordisk, and Rhythm Pharmaceuticals. SM and CP received travel funds from the following company, which was involved with lipodystrophy: Amryt Pharmaceuticals. FS has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt, Novo Nordisk, Lilly, Bruno Pharma, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: All authors have read and agreed to the published article.
: This article does not contain any studies with animals performed by any of the authors.